---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-22-000003"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2022-02-01T23:59:59+00:00"
generated_at: "2026-06-27T13:18:30.856617+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gilead Q4 GAAP EPS $0.30, revenue $7.2B (-2% YoY); 2022 guidance $23.8-24.3B

## Summary
- GAAP diluted EPS $0.30 vs $1.23 YoY; non-GAAP $0.69 vs $2.19 (includes $1.25B legal charge)
- Q4 product sales $7.2B (-2% YoY); ex-Veklury up 8% to $5.8B
- Biktarvy sales up 22% YoY to $4.5B; Cell Therapy up 47% to $239M
- 2022 guidance: product sales $23.8-24.3B; GAAP EPS $4.70-5.20; non-GAAP EPS $6.20-6.70
- Cash flow: $3.2B operating; debt repayment $1B; dividends $894M; cash $7.8B at Dec 31

## SEC filing metadata
- accession: 0000882095-22-000003
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2022-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209522000003/0000882095-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209522000003/gild-20220201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-22-000003
- JSON: https://secwatch.observer/filing/0000882095-22-000003.json
- Plain text: https://secwatch.observer/filing/0000882095-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.